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Abstract: Background and aims: Dietary berries, such as strawberries, are rich in bioactive com-
pounds and have been shown to lower cardiometabolic risk. We examined the effects of two dietary
achievable doses of strawberries on glycemic control and lipid profiles in obese adults with elevated
serum LDL cholesterol (LDL-C). Methods: In this 14-week randomized controlled crossover study,
participants were assigned to one of the three arms for four weeks separated by a one-week washout
period: control powder, one serving (low dose: 13 g strawberry powder/day), or two-and-a -half
servings (high dose: 32 g strawberry powder/day). Participants were instructed to follow their usual
diet and lifestyle while refraining from consuming other berries and related products throughout the
study interval. Blood samples, anthropometric measures, blood pressure, and dietary and physical
activity data were collected at baseline and at the end of each four-week phase of intervention.
Results: In total, 33 participants completed all three phases of the trial [(mean ± SD): Age: 53 ± 13 y;
BMI: 33 ± 3.0 kg/m2). Findings revealed significant reductions in fasting insulin (p = 0.0002) and
homeostatic model of assessment of insulin resistance (p = 0.0003) following the high dose strawberry
phase when compared to the low dose strawberry and control phases. Glucose and conventional
lipid profiles did not differ among the phases. Nuclear magnetic resonance-determined particle
concentrations of total VLDL and chylomicrons, small VLDL, and total and small LDL were signifi-
cantly decreased after the high dose strawberry phase, compared to control and low dose phases (all
p < 0.0001). Among the biomarkers of inflammation and adipokines measured, only serum PAI-1
showed a decrease after the high dose strawberry phase (p = 0.002). Conclusions: These data suggest
that consuming strawberries at two-and-a-half servings for four weeks significantly improves insulin
resistance, lipid particle profiles, and serum PAI-1 in obese adults with elevated serum LDL-C.
Keywords: strawberries; obesity; insulin resistance; LDL cholesterol; small LDL particles; plasmino-
gen activator inhibitor-1
1. Introduction
Historically, fruits and vegetables, as plant-based food groups, have been promoted
for various health benefits, especially in the context of reducing risks of adiposity, type
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2 diabetes, cancer, and cardiovascular disease (CVD) [1,2]. Several components in fruits
and vegetables are identified for their physiological effects in reducing risks of chronic
diseases among which the phytochemicals deserve special attention [3,4]. The benefits of
commonly consumed whole berry fruits, especially blueberries and strawberries, have
been emphasized for their distinct effects in improving metabolic syndrome, a constellation
of diabetes and CVD risks [5]. These improvements are ascribed mainly via mediating
weight loss and reducing blood pressure at recommended levels of intakes [6]. Most of the
health benefits of berry fruits, especially blueberries, cranberries, and strawberries, have
been explained by their high polyphenol and fiber content, and concomitant low caloric
contributions to the diet [7,8]. Despite this scientific evidence on why whole fruits and
vegetables must be essential food groups in the daily diet, US adults have continued low
intake of fruits and vegetables associated with increased risk of type 2 diabetes and CVD [9].
To address these dietary deficiencies and to overcome the behavioral challenge of changing
one’s entire habitual diet to a healthy diet, whole berries have been supplemented as
functional foods in several clinical trials yielding favorable compliance and improvement
in cardiometabolic risks.
Among several CVD risks widely observed in the global population, metabolic syn-
drome [10] with elevated blood lipids such as total and LDL cholesterol [11,12] remains
prominent. Dietary berries have been demonstrated to reduce these risks in clinical tri-
als [13,14]. However, the reported findings are inconsistent, and experimental heterogeneity
among doses and forms of different berries, study duration, outcomes reported, and partici-
pant characteristics make concrete recommendations challenging. To address this issue, our
group has reported a series of clinical studies, mainly to assess the optimal dose and effects
of whole strawberries on cardiometabolic risk in adults with features of the metabolic
syndrome [15–17]. In our previously reported studies, strawberry supplementation was
shown to decrease total and LDL cholesterol in overall healthy adults with abdominal
obesity and dyslipidemia [15,16]. Most of these lipid-lowering effects were observed in
the group consuming a large dose of freeze-dried powder equivalent to a pound of fresh
strawberries daily. Thus, we conducted the current trial using dietary achievable doses of
strawberries, equivalent to one serving, and two-and-a-half servings of strawberries daily
using a randomized controlled crossover design in obese adults and LDL-cholesterol above
optimal levels. We hypothesized that dietary strawberry supplementation, administered as
freeze-dried strawberry powder, will improve cardiometabolic risk in these adults when
compared to the control group over a 14-week duration.
2. Materials and Methods
This is a multicenter, randomized, double-blind controlled, crossover trial conducted
at the Oklahoma Clinical and Translational Sciences Institute (OCTSI) at the University of
Oklahoma Health Sciences Center (OUHSC), Department of Nutritional Sciences at the
Oklahoma State University (OSU), and the Section of Endocrinology at the University of
Nevada at Las Vegas (UNLV) School of Medicine. The study was approved by the OUHSC,
OSU, and UNLV Institutional Review Boards (IRB number 1119274) and was registered at
Clinicaltrials.gov (Identifier: NCT03441620). All participants provided written informed
consent.
2.1. Study Criteria and Protocol
Participants were recruited using the campus system of email communication to all
faculty, staff, and students at each of the three sites, as well as by flyers posted at build-
ings, such as the student wellness centers and the academic advising centers on each
campus. Adult men and women with one or more features of metabolic syndrome [5],
abdominal adiposity (waist circumference: men >40 inches; women >35 inches), body
mass index (BMI) in the obese range (≥30 kg/m2), and elevated serum LDL cholesterol
(LDL-C) > 116 mg/dL were enrolled in the study. Exclusion criteria were current use of
medications that may influence glucose and lipid metabolism (metformin, statins, glucocor-
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ticoids, immunosuppressants, antipsychotics), unwillingness or inability to provide written
informed consent, or significant underlying medical disorder assessed by the study physi-
cian (e.g., anemia, renal disorders, diabetes), and smokers. Participants were also excluded
if they were allergic to berries, were unwilling to make dietary changes, or were vegetarian
or consuming any other special diet not consumed habitually. Using a crossover design,
participants completed three, four-week interventions in a randomized counterbalanced
order using a Latin Square Design. During each four-week period, participants consumed
beverages reconstituted with water from control powder, or freeze-dried strawberry pow-
ders equivalent to one serving, or two-and-a-half servings of strawberries each day. There
was a one-week washout phase between each phase. Participants were instructed to follow
their usual diet and lifestyle habits throughout the 14-week study. Health and medical
history, anthropometric measurements, blood pressure recordings, and blood draws were
obtained at baseline and at the end of each four-week intervention phase. In addition to
these visits, participants made biweekly short visits to the clinic to meet the registered
dietitian (RD) and nurse practitioner, receive supplies of the test agents, and submit 24 h
diet recalls.
2.2. Intervention and Control Powders
The composition of the control and freeze-dried strawberry powders, provided by
the California Strawberry Commission (Watsonville, CA, USA) is shown in Table 1. These
powders were provided to the participants in vacuum-sealed packets to be reconstituted
with plain drinking water for consumption. The total volume of powder provided was sim-
ilar for all three groups (~32 g/day) and was consumed in two separate doses at least six to
eight hours apart. The participants were also asked to consume the reconstituted beverage
by itself and not with a meal or other snacks to prevent the confounding effects of other
dietary factors. Participants were provided with uniform instructions to consume the test
beverage at least two hours after the main meal or snack, and preferably as a midmorning
and early evening snack during the day. The control powder was formulated to match the
sensory properties of the strawberry powder, as well as its caloric value and macronutrient
composition. The nutrient and phytochemical composition of the strawberry and control
powders was determined at the Robert M. Kerr Food and Agricultural Products Center
at Oklahoma State University (Stillwater, OK, USA), and at the Brunswick Laboratories
(Southborough, MA, USA), respectively.
Table 1. Composition of test powders consumed per day.
Variable Control Strawberry-LD Strawberry-HD
Weight, g 32 32 32
Calories, Kcal 122 123 124
Total Carbohydrates, g 29 28 27
Ash, g 1.1 0.7 2.0
Dietary fiber, g 3.2 2.1 5.0
Vitamin C, mg ND 26 65
Total phenolics, mg 1 ND 400 960
Total anthocyanins, mg 2 ND 38 92
Total ellagic acid, mg ND 9 25
Total flavan-3-ols, mg ND 24 60
HD = high dose (~32 g powder or 2.5 servings of strawberries/day); LD = low dose (~13 g powder or 1.0
serving of strawberries/day); ND = not detectable. 1 Expressed as mg gallic acid equivalents. 2 Expressed as mg
cyanidin-3-glucoside equivalents.
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2.3. Habitual Dietary Intake and Physical Activity Assessment
All study participants were asked to maintain a 24 h food recall each week, which
they submitted to the RD during their biweekly visits and discussed any changes made in
their habitual diet. All participants were otherwise expected to maintain their usual diet
and level of physical activity throughout the study. Participants were also asked to refrain
from consuming additional strawberries other than the freeze-dried powders provided in
the study. Dietary analyses were conducted by the study RD or a trained dietetic assistant
using the ESHA’s Food Processor® Nutrition Analysis software for energy, nutrients, and
food group intake for each participant. Self-reported physical activity participation was
quantified by the International Physical Activity Questionnaire Short Form (IPAQ–SF),
which assesses physical activity levels during the last seven days, and participant responses
(yes/no) were recorded for meeting exercise recommendations (≥150 min of moderate
and/or ≥90 min vigorous exercise/week) [18].
2.4. Compliance
Compliance was assessed based on the return of unused packets of the test powders
at the end of each four-week phase of the study. Each participant also received weekly
phone calls from the study team to ensure the timely consumption of control or strawberry
beverages and to discuss general dietary concerns with the participants. Participants were
also reminded to maintain their weekly 24 h food recalls. Serum ellagic acid was measured
in the intervention groups as a marker of strawberry consumption using published meth-
ods [19]. The incidence and persistence of any side effects in the intervention groups, i.e.,
gastrointestinal symptoms and headaches were recorded.
2.5. Anthropometric Measures and Blood Pressure
Participant body weight, height, waist circumference, systolic and diastolic blood
pressure were measured at baseline and at the end of each four-week phase of the trial.
Body weight was measured using a digital scale in light clothing and no shoes. Systolic
and diastolic blood pressure was measured in mm Hg using Spot Vital Signs Device (Welch
Allyn, Skaneateles Falls, NY, USA). At each visit, participants were asked to lie down and
relax for approximately 8–10 min, following which three blood pressure measurements
were recorded at intervals of 5–8 min and mean values were recorded.
2.6. Biochemical Analyses
At each visit (baseline and end of each four-week phase) freshly drawn blood samples
were sent to the University of Oklahoma Medical Center laboratory (Oklahoma City, OK,
USA) or Quest Diagnostics (Las Vegas, NV, USA) for analyses of serum glucose and conven-
tional lipid profiles, insulin, liver, and kidney function tests (Abbott Architect Instruments)
with commercial kits, according to manufacturer’s protocols. C-reactive protein was as-
sayed by ultrasensitive nephelometry (Dade Behring). Serum glycated hemoglobin was
analyzed with the use of a DCA 2000+ Analyzer (Bayer). Insulin resistance was evaluated
by HOMA-IR and was calculated as follows: [fasting insulin (mU/L) × fasting glucose
(mmol/L)]/22.5 [20]. Nuclear magnetic resonance-determined lipoprotein subclass profile
(NMR-LSP) was performed in first-thaw plasma specimens using a 400-MHz proton NMR
analyzer at LipoScience Inc. (Morrisville, NC), as described previously [21]. In addition,
sera were stored at −80 ◦C for the subsequent analyses of diabetes-related hormones and
adipokines. Serum adiponectin was measured using a quantitative sandwich enzyme im-
munoassay technique (R&D Systems, Minneapolis, MN, USA) with an average intra-assay
CV of 4.8%.
2.7. Human Diabetes Panel Assays
Diabetes-related adipokines and hormones were determined in available first-thaw
serum samples at baseline and at the end of each four-week intervention phase. These were
measured using Bio-Plex Pro™ Human Diabetes Panel magnetic bead assays (Bio-Rad
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Laboratories, Hercules, CA, USA), according to the manufacturer’s instructions. Frozen
serum samples were thawed on ice and 1:3 dilutions were prepared with the sample diluent
provided in the kit. Diluted samples were processed using the manufacturer’s protocol
with the following modifications: (i) beads were incubated with the detection antibodies for
45 min; and (ii) beads were incubated with streptavidin–phycoerythrin antibody for 20 min.
The variables measured and their corresponding intra-assay CVs were C-peptide ~4%,
ghrelin ~4%, gastric inhibitory polypeptide (GIP) ~3%, glucagon-like peptide-1 (GLP-1)
~4%, glucagon ~5%, leptin ~3%, plasminogen activator inhibitor-1 (PAI-1) ~2.5%, resistin
~5%, and visfatin ~4%.
2.8. Statistical Analyses
All data were examined for normal distribution using Shapiro–Wilk test and Skew-
ness/Kurtosis. No outliers were detected. Continuous variables were expressed as
means ± SD and discrete variables as counts and percentages. We employed a mixed
model ANOVA to examine the main effects of treatment, time, and interaction to examine
differences in outcomes at the end of each four-week phase of intervention. Baseline
values were included as covariates for each outcome variable. Outcomes were modeled
as repeated measures, with subject as a random effect and with unstructured variance for
treatment/time. When time and treatment-by-time interactions were nonsignificant, they
were removed from the model. When time effects were significant, they were retained
in the final model of treatment effects. The sequence of intervention was included in all
models to test for carryover effects, and none were detected. Our previous strawberry
study in adults with the metabolic syndrome [15,16], indicated a difference in serum LDL
cholesterol of 12 ± 8 mg/dL (mean ± SD) and of small LDL particle concentrations of
108 ± 52 nmol/L would be expected using a sample size of 16/group within the four
weeks of strawberry treatment to achieve 80% power at 0.05 α level. Considering a 20–30%
attrition, we aimed to recruit and retain at least 21 participants in the crossover study. All
p-values were two-tailed, and main effects and interaction effects were considered if <0.05.
Analyses were performed using SAS (version 9.4; SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Baseline Characteristics and Compliance
The study enrollment is shown in Figure 1. Table 2 presents the baseline characteristics
of the 33 participants who completed all three phases of the randomized crossover study.
Based on the completion of self-reported daily consumption logs and return of unused pow-
der, protocol compliance was 96%. In addition, ellagic acid was measured in serum samples
and revealed the following levels (means ± SD): baseline: not detectable; control: not de-
tectable; low-dose strawberry: 15 ± 8 nmol/L; high-dose strawberry: 27 ± 13 nmol/L.
Table 2. Baseline characteristics of study participants.
N 33
Age, (y) 53 ± 13
Sex, (M/F) 2/31
BMI, (kg/m2) 33 ± 3
Blood pressure medication use, n (%) 6 (18)
Antidepressant use, n (%) 8 (24)
Multivitamin use, n (%) 5 (15)
Meeting exercise recommendations (%) 1 11 (33)
Data are presented as mean and standard deviations (SD). Count data presented as n (%). M = male; F = female;
BMI= body mass index. 1 ≥150 min of moderate and/or ≥90 min vigorous exercise/week.
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3.2. Anthropometrics, Blood Pressure, Glucose, Insulin, and Conventional Lipids
Among the biomarkers of glycemic control, a significant main effect of treatment was
observed for serum insulin and insulin resistance (HOMA-IR), which revealed significantly
lower values after the high dose strawberry phase, compared to values in the baseline,
control, and low dose strawberry phases in post hoc analyses (p = 0.0002 and p = 0.0003,
respectively; Table 3). No treatment effects were noted for serum glucose and HbA1c. In
the conventional lipid profile, a borderline significant effect of treatment was noted for
serum LDL cholesterol, which revealed lower values after the high-dose strawberry phase,
compared to values in the baseline, control, and low-dose strawberry phases in post hoc
analyses (p = 0.05; Table 3). No treatment effects were noted with serum total and HDL
cholesterol and triglycerides. Similarly, no main effects of treatment were noted for body
weight, BMI, and waist circumference, as well as systolic and diastolic blood pressure
related to the strawberry intervention. Overall, treatment-by-time interactions were not
significant for any of the outcomes except for serum insulin (p = 0.005), indicating that
the effect of the treatment on insulin depended on the order in which the treatments were
administered.
Table 3. Cardio–metabolic profiles in obese adults with above optimal serum LDL cholesterol following each treatment








Body weight, lb 189 ± 23 189 ± 23 190 ± 23 190 ± 23 0.99
BMI, kg/m2 32.0 ± 2.5 32.0 ± 2.4 32.0 ± 2.5 32.0 ± 2.4 0.89
Waist circumference, inches 40.0 ± 2.8 41.0 ± 3.0 41.0 ± 3.0 41.0 ± 3.0 0.92
Systolic blood pressure, mm Hg 127 ± 8 126 ± 10 127 ± 9 124 ± 8 0.78
Diastolic blood pressure, mm Hg 82 ± 7 82 ± 8 80 ± 7 80 ± 8 0.84
Serum total cholesterol, mg/dL 221 ± 28 217 ± 28 209 ± 34 208 ± 32 0.24
Serum LDL cholesterol, mg/dL 144 ± 25 139 ± 23 133 ± 29 127 ± 24 0.05
Serum HDL cholesterol, mg/dL 54 ± 10 53 ± 11 53 ± 11 53 ± 9 0.96
Serum LDL:HDL 2.8 ± 0.9 2.8 ± 0.9 2.7 ± 0.9 2.6 ± 0.8 0.77
Serum Triglycerides, mg/dL 124 ± 66 126 ± 60 128 ± 67 133 ± 76 0.95
Serum Fasting glucose, mg/dL 93 ± 13 93 ± 12 94 ± 11 93 ± 15 0.97
Serum HbA1c, % 5.5 ± 0.3 5.5 ± 0.3 5.5 ± 0.3 5.5 ± 0.2 0.95
Serum Insulin, µIU/mL * 15.4 ± 6.6 a 15.2 ± 6.4 a 14.0 ± 8.2 a 9.1 ± 3.1 b 0.0002
Serum HOMA-IR 3.6 ± 1.5 a 3.5 ± 1.4 a 3.3 ± 2.0 a 2.1 ± 0.5 b 0.0003
Serum hs-CRP, mg/L 4.3 ± 3.2 4.4 ± 3.5 4.3 ± 3.1 3.8 ± 2.9 0.85
Serum adiponectin, µg/mL 9.3 ± 5.7 10.5 ± 6.2 11.4 ± 5.2 11.7 ± 7.2 0.84
Data presented as means ± SD. N = 33/group. BMI= body mass index; HD = high dose (~2.5 servings of strawberries/day);
HOMA-IR = homeostasis model assessment of insulin resistance; hs-CRP = high sensitivity C-reactive protein; LD = low dose (~1.0
serving of strawberries/day). 1 p for main effect of treatment from the MIXED procedure (SAS version 9.4; SAS Institute Inc., Cary, NC,
USA) adjusted for baseline values. Different superscript letters show significant differences among treatment groups for each variable.
p < 0.05 in bold font. * p for time effect significant with lower values at 14 weeks, compared to baseline and four weeks (p < 0.05).
3.3. NMR-Derived Lipid Particle Profiles
Among the NMR-derived lipid particle concentrations and size, several main effects
of treatment were noted. Total particle concentrations of VLDL and chylomicrons, as
well as small VLDL particles, and total LDL and small LDL particle concentrations were
significantly lower at the end of the high-dose strawberry phase, compared to values
following the low-dose strawberry, baseline, and/or control phases in post hoc analyses (all
p < 0.0001; Table 4). No significant effects were noted in HDL particle concentrations. On
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the other hand, HDL particle size was significantly increased after the low-dose strawberry
phase, compared to values in the baseline, control, and high-dose strawberry phases in
post hoc analyses (p < 0.0001; Table 4). No effects were detected with VLDL and LDL
particle size. Overall, treatment-by-time interactions were not significant for any of the
outcomes except for small LDL particle concentration (p = 0.004), indicating that the effect
of the treatment on small LDL particles depended on the order in which the treatments
were administered.
Table 4. Plasma NMR-derived lipid particle concentrations and size in obese adults with above optimal serum LDL








VLDL and chylomicron particles
(total), nmol/L 39.2 ± 16.3
a 41.7 ± 15.9 a 42.6 ± 16.0 a 32.3 ± 13.0 b <0.0001
Large VLDL and chylomicron
particles, nmol/L 6.1 ± 3.9 6.7 ± 3.7 6.8 ± 3.7 6.3 ± 3.2 0.06
Medium VLDL particles, nmol/L 12.9 ± 9.5 14.3 ± 9.3 14.3 ± 9.3 12.7 ± 8.8 0.07
Small VLDL particles, nmol/L 21.8 ± 10.2 22.3 ± 10.8 a 23.1 ± 10.0 a 13.7 ± 5.4 b <0.0001
LDL particles (total), nmol/L * 1126 ± 328 1196 ± 326 a 1204 ± 310 a 1042 ± 297 b <0.0001
IDL particles, nmol/L 341 ± 175 359 ± 173 362 ± 169 357 ± 174 0.12
Large LDL particles, nmol/L 153 ± 99 152 ± 93 152 ± 92 150 ± 93 0.76
Small LDL particles (total), nmol/L * 638 ± 188 a 695 ± 242 a,b 681 ± 219 a,b 535 ± 140 b <0.0001
HDL particles (total), µmol/L 29.1 ± 5.6 29.5 ± 5.8 30.0 ± 5.7 29.5 ± 5.8 0.18
Large HDL particles, µmol/L 4.2 ± 1.9 4.4 ± 1.8 4.5 ± 1.8 4.2 ± 1.7 0.11
Medium HDL particles, µmol/L 5.5 ± 4.7 5.6 ± 4.8 6.0 ± 4.9 5.6 ± 4.7 0.24
Small HDL particles, µmol/L 19.5 ± 5.1 20.1 ± 4.6 20.7 ± 4.1 20.0 ± 4.7 0.22
VLDL size, nm 55.4 ± 7.1 55.5 ± 7.7 55.9 ± 8.0 54.1 ± 7.8 0.35
LDL size, nm 20.1 ± 0.6 20.8 ± 1.8 21.3 ± 1.9 20.2 ± 1.9 0.45
HDL size, nm 9.2 ± 0.5 a 9.2 ± 0.7 a 11.3 ± 2.4 b 9.3 ± 0.7 a <0.0001
Data presented as means ± SD. N = 33/group. HD = high dose (~2.5 servings of strawberries/day); LD = low dose (~1.0 serving of
strawberries/day); NMR = nuclear magnetic resonance. 1 p for main effect of treatment from the MIXED procedure (SAS version 9.4; SAS
Institute Inc., Cary, NC, USA) adjusted for baseline values. Different superscript letters show significant differences among treatment
groups for each variable. p < 0.05 in bold font. * p for time effect significant with lower values at 14 weeks, compared to baseline and four
weeks (p < 0.05).
3.4. Adipokines, CRP, and Hormonal Biomarkers
Among the adipokines, a significant treatment effect was observed for serum PAI-
1, which revealed significantly lower values following the high-dose strawberry phase,
compared to values after the baseline, control, and low-dose strawberry phases in post
hoc analyses (p = 0.002; Table 5). On the other hand, no effects were observed with serum
leptin, resistin, and visfatin (Table 5), as well as for CRP and adiponectin (Table 3). Among
the hormonal biomarkers, a significant treatment effect was observed for serum glucagon,
which revealed significantly higher values in the high-dose strawberry phase, compared
to values in the baseline, control, and low-dose strawberry phases in post hoc analyses
(p = 0.02; Table 5). No effects were found on serum C-peptide, ghrelin, GIP, and GLP-1
(Table 5). Overall, treatment-by-time interactions were not significant for any of these
outcomes except for serum PAI-1 (p = 0.003), indicating that the effect of the treatment on
PAI-1 depended on the order in which the treatments were administered.
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Table 5. Diabetes-related adipokines and hormonal markers in obese adults with above optimal serum LDL cholesterol








Serum C-peptide, pg/mL 1232 ± 929 1273 ± 531 1254 ± 752 1021 ± 680 0.68
Serum ghrelin, pg/mL 486 ± 371 371 ± 361 380 ± 319 482 ± 392 0.62
Serum GIP, pg/mL 478 ± 357 354 ± 274 378 ± 219 564 ± 426 0.23
Serum GLP-1, pg/mL 314 ± 59 265 ± 47 288 ± 69 307 ± 88 0.23
Serum glucagon, pg/mL 654 ± 147 609 ± 93 635 ± 113 725 ± 117 0.02
Serum leptin, pg/mL 13736 ± 9204 12795 ± 4841 14884 ± 7433 9547 ± 3635 0.09
Serum PAI-1, pg/Ml * 5621 ± 1022 5812 ± 1240 5245 ± 1278 4315 ± 1434 0.002
Serum resistin, pg/mL 10487 ± 6799 11787 ± 6516 11711 ± 6238 10199 ± 4811 0.82
Serum visfatin, pg/mL 3240 ± 1310 2733 ± 1033 2797 ± 954 3176 ± 1352 0.45
Data presented as means ± SD. N = 33/group. GIP = gastric inhibitory polypeptide; GLP-1 = glucagon-like peptide-1; HD = high dose
(~2.5 servings of strawberries/day); LD = low dose (~1.0 serving of strawberries/day); PAI-1 = plasminogen activator inhibitor-1. 1 p for
main effect of treatment from the MIXED procedure (SAS version 9.4; SAS Institute Inc., Cary, NC, USA) adjusted for baseline values.
Different superscript letters show significant differences among treatment groups for each variable. p < 0.05 in bold font. * p for time effect
significant with lower values at 14 weeks, compared to baseline and four weeks (p < 0.05).
3.5. Habitual Dietary Intakes and Physical Activity
No significant differences were noted in the habitual intake of dietary nutrients, as
well as total intake of fruits and vegetables for participants throughout the study and
across the different phases (Table 6). Similarly, physical activity data showed no significant
treatment and time effects in the participants.
Table 6. Background daily dietary nutrient and food group intakes in obese adults with above optimal serum LDL








Total calories, kcal 2012 ± 152 1988 ± 183 2123 ± 113 2067 ± 193 0.74
Carbohydrates, % kcal 45 ± 6 48 ± 8 44 ± 5 46 ± 8 0.66
Fats, % kcal 34 ± 4 36 ± 7 35 ± 5 37 ± 5 0.45
Proteins, % kcal 20 ± 5 16 ± 6 21 ± 7 17 ± 6 0.42
Total sugars, g * 85 ± 11 78 ± 12 72 ± 9 75 ± 10 0.08
Fiber, g 15 ± 11 18 ± 12 22 ± 15 21 ± 10 0.18
Vitamin E, mg 9 ± 2 11 ± 4 11 ± 2 10 ± 4 0.22
Vitamin C, mg 45 ± 13 46 ± 12 49 ± 12 49 ± 12 0.26
Fruits, cups 1.0 ± 0.4 1.0 ± 0.3 0.8 ± 0.2 1.0 ± 0.4 0.45
Vegetables, cups 1.3 ± 0.2 1.1 ± 0.3 0.9 ± 0.2 1.1 ± 0.4 0.38
Data presented as means ± SD. N = 33/group. HD = high dose (~2.5 servings of strawberries/day); LD = low dose (~1.0 serving of
strawberries/day). 1 p for main effect of treatment from the MIXED procedure (SAS version 9.4; SAS Institute Inc., Cary, NC, USA) adjusted
for baseline values. * p for time effect significant with lower values at 14 weeks, compared to baseline and four weeks (p < 0.05).
4. Discussion
The present study demonstrates the role of dietary strawberries at a daily dose of
two-and-a-half servings in decreasing serum insulin and concomitant insulin resistance
(HOMA-IR), but not fasting glucose in obese adults with features of the metabolic syndrome.
Attributable to this decrease in serum insulin, we also observed an increase in serum
glucagon and a decrease in serum PAI-1 with this dose of strawberries. While significant
improvements were not observed in conventional lipids, the results revealed a decrease
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in serum LDL cholesterol, which was borderline significant. Further, the higher dose of
strawberries also resulted in improvements in lipid particle concentrations, especially in
decreasing VLDL and chylomicron particles, as well as total and small LDL particles, all of
which have important consequences in decreasing atherogenic risk in these adults. The
daily lower dose of dietary strawberries of one serving did not lead to many changes,
except an increase in HDL particle size. Given the projected increase in the global incidence
of type 2 diabetes [22], in which insulin resistance plays a key role, our findings are of
relevance in decisions regarding public health nutrition.
To our knowledge, this is the first study to document the role of strawberries in
improving insulin resistance in a nonacute setting for four weeks in at-risk adults. Our
findings on the role of high-dose strawberries (~960 mg total polyphenols) in improving
insulin resistance are corroborated by several reported clinical studies using different vari-
eties of dietary berries. Using a combination of strawberry and cranberry polyphenols (333
mg for six weeks), Paquette et al. reported significant increases in insulin sensitivity, and a
decrease in first-phase insulin secretion when compared to the control group in adults with
insulin resistance [23]. In another study, feeding freeze-dried blueberry powder (1462 mg
polyphenols for six weeks) also revealed improvements in insulin sensitivity in adults with
metabolic syndrome [24]. Other feeding trials using cranberry juice polyphenols (~346 mg
polyphenols for eight weeks) have also revealed similar [25,26] but some inconsistent re-
sults [27] on insulin resistance and glucoregulation in adults with cardiometabolic risks. In
an acute study using a slightly higher dose of strawberries than what was used in our study
(40 g strawberry powder; ~three servings of fresh strawberries), Park et al. reported a de-
crease in six-hour postprandial insulin load when compared to the control group in adults
with insulin resistance [28]. Their findings, together with our report, provide evidence
that strawberries at a dose of two-and-a-half to three servings a day or when taken with
meals could reduce the pancreatic burden of greater insulin secretion by reducing insulin
resistance and yet maintaining normal blood glucose levels. These observations have been
explained by mechanistic studies reporting the role of strawberry polyphenols and dietary
polyphenols for improving insulin signaling and inflammation in animal models of insulin
resistance and diabetes [29–32]. These findings warrant further investigation in adults with
type 2 diabetes regarding the use of strawberry polyphenols, alone and in combination
with other dietary polyphenols, to examine maximal efficacy on impaired glycemia.
In contrast to our previous findings on the role of freeze-dried strawberry powder in
reducing total and LDL cholesterol [15,16], the present study revealed a borderline signifi-
cant lowering of LDL cholesterol in the high-dose strawberry phase. These differences may
be attributed to the shorter duration of each phase in the current study and dose differences
when compared to our previous trial. Nonetheless, these improvements within a short
duration in adults with elevated LDL cholesterol are of clinical and public health relevance
based on the increased global CVD mortality rates that can be attributable to elevated LDL
cholesterol [12]. NMR-derived lipid profiles revealed atherogenic profiles that are often
not identified in conventional lipids [33], that is, total particle concentrations of VLDL and
small LDL particles have been associated with increased CVD risk and have been the target
for therapeutic interventions in patient-oriented studies [21,34]. In this context, the present
study observations of strawberries decreasing these atherogenic lipid particles confirm
our [16] and other [35] previously reported findings. The lipid-lowering effects of straw-
berries may be explained by the fruit fiber, phytosterols, and a combination of polyphenols
that interfere with lipid digestion, absorption, and excretion [36,37]. These confirmatory
findings further strengthen the evidence on the role of strawberries in improving CVD
risks and preventing disease progression.
Our findings on the effect of high-dose strawberries in decreasing serum PAI-1 levels
are novel and are consistent with a single reported acute study in which coadministration of
freeze-dried strawberry powder (~95 mg total polyphenols) caused a significant decrease in
postprandial PAI-1 levels when compared to those consuming no strawberries [38]. Insulin
resistance has been associated with increased expression of PAI-1 by human adipocytes [39]
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and increased PAI-1 with inflammation and CVD risks [40,41]. Our observed decreases in
serum PAI-1 may be attributable to the downstream effects of improved insulin resistance
with high-dose strawberry supplementation. Our findings are corroborated by mechanistic
studies demonstrating decreased PAI-1 expression by dietary polyphenols [42,43]. On the
other hand, we did not observe any differences in other biomarkers of obesity including
serum leptin, adiponectin, CRP, resistin, and visfatin, which could be explained by the
short duration of each phase of the intervention, and no difference in body weight status in
these participants.
Our study has several strengths. Our randomized crossover study design addresses
the high interindividual variabilities observed in a parallel trial. Our study simultaneously
examined two different dietary achievable doses of whole strawberries administered as
freeze-dried powder. This design addressed a gap in dosing consideration since most
studies have used higher doses or a single dose of berries that do not reflect habitual
consumption and therefore lack sustainability. We report detailed lipid profiles, including
concentrations of individual lipid particles and particle size, which have been reported by
few clinical studies examining the effects of berry ingestion in adults. Additionally, based
on the administration of a control powder that matched the freeze-dried strawberries in
sensory qualities, we were able to keep the participants and study coordinators blinded to
the test agents. In addition, we excluded participants on medications for lowering lipids
and diabetes, as well as those participating in a weight loss program, and thus were able to
minimize potential confounding by these factors. In the same context, our study also had a
limitation by excluding participants taking medications for lowering blood glucose and
lipids, and this may limit the generalizability of our findings to the larger adult population
who typically are on these prescriptions. Additionally, although the total study duration
was 14 weeks, each phase of the intervention lasted for only four weeks, and this could
explain some of the limited effects on cardiometabolic biomarkers. Moreover, we only
measured a selected set of inflammatory and adipokine biomarkers, which have been
associated with obesity and insulin resistance, and thus, future studies should examine
a more comprehensive panel of the types of biomolecules, including antioxidant factors,
that would modulate disease outcomes following strawberry supplementation. Finally, the
short one-week washout phase between control and treatment phases may have led to some
carryover effect, and this limitation is inherent in a crossover study design. Additionally,
we did not measure the biomarkers at the end of the washout phase since we do not expect
metabolic markers to differ significantly within a week.
In conclusion, our randomized controlled crossover trial supports the hypothesis
that dietary strawberries when consumed at a dose of two-and-a-half servings a day
significantly improve cardiometabolic risks, mainly via improving insulin resistance and
atherogenic lipid particles, when compared to the control group. When consumed at a
dose of one serving of strawberries, modest effects were observed for improving HDL
particle size. These findings support the role of dietary strawberries in a medical nutrition
therapeutic approach for diabetes prevention in adults.
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